Medicine and Dentistry
Radiation Therapy
100%
Disease
63%
Neck
51%
Overall Survival
50%
Head and Neck Cancer
44%
Recurrent Disease
42%
Chemoradiotherapy
41%
Head and Neck Squamous Cell Carcinoma
38%
Non Small Cell Lung Cancer
36%
Intensity Modulated Radiation Therapy
36%
Distant Metastasis
31%
Cisplatin
24%
Oropharynx Squamous Cell Carcinoma
24%
Randomized Clinical Trial
24%
Squamous Cell Carcinoma
22%
Oropharyngeal Cancer
20%
Progression Free Survival
18%
Wart Virus
18%
Neoplasm
17%
Induction Chemotherapy
16%
Lung Cancer
15%
Clinical Trial
15%
Malignant Neoplasm
15%
Adjuvant Therapy
14%
Lymphadenopathy
13%
Cohort Analysis
13%
Hypofractionated Radiotherapy
13%
Quality of Life
13%
Disease Exacerbation
13%
Phase II Trials
13%
Trastuzumab
12%
Cetuximab
12%
Lower Jaw
12%
Epidermal Growth Factor Receptor 2
12%
Contralateral
12%
Pemetrexed
12%
Neck Radiotherapy
12%
Therapy Delay
12%
Tonsil Cancer
12%
Oral Cancer
12%
Head Radiotherapy
12%
Acute Liver Failure
12%
Adenocarcinoma
12%
Non-Hodgkin Lymphoma
12%
Maintenance Chemotherapy
12%
Gamma Urogastrone
12%
Carboplatin
12%
Opiate
12%
COVID-19
12%
Neuroendocrine Tumor
12%
Keyphrases
Head-and-neck
49%
Head-and-neck Cancer
46%
Radiation Therapy
36%
Cisplatin
28%
Distant Metastasis
26%
Radiotherapy
25%
Cetuximab
24%
Metastatic Non-small Cell Lung Cancer
24%
Non-small Cell Lung Cancer (NSCLC)
24%
Randomized Clinical Trial
24%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
24%
Overall Survival
21%
Squamous Cell Cancer
21%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
19%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
18%
Hypofractionation
16%
Poor Performance Status
16%
Phase II Trial
15%
Retrospective Cohort Analysis
15%
Confidence Interval
14%
Maximum Tolerated Dose
14%
Progression-free Survival
14%
Intensity-modulated Radiotherapy
14%
Phase II Study
13%
Single Institution
13%
Weekly Cisplatin
13%
Nab-paclitaxel
12%
Hospital-based
12%
Multi-institutional
12%
Primary Surgery
12%
Clinical Practice
12%
High-risk Human Papillomavirus (HR-HPV)
12%
Pemetrexed
12%
Cutaneous Adenocarcinoma
12%
Second Primary Squamous Cell Carcinoma
12%
Immunotherapy Toxicity
12%
Hypofractionated Radiation Therapy
12%
Treatment Regimen
12%
Conventional Radiotherapy
12%
Carboplatin
12%
Treatment Delay
12%
Stage II-III
12%
Unique Pattern
12%
Concurrent Radiation
12%
Locally Advanced
12%
Adjuvant Therapy
12%
Phase I Trial
12%
Nodal Radiotherapy
12%
Chest Radiation
12%
Extracapsular Extension
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
61%
Chemotherapy
49%
Overall Survival
46%
Chemoradiation Therapy
41%
Disease
38%
Lung Cancer
28%
Progression Free Survival
26%
Carboplatin
24%
Cisplatin
24%
Randomized Clinical Trial
24%
Recurrent Disease
21%
Head and Neck Squamous Cell Carcinoma
20%
Head and Neck Cancer
18%
Disease Exacerbation
16%
Phase II Trials
13%
Cetuximab
12%
Paclitaxel
12%
Squamous Cell Carcinoma
12%
Human Papillomavirus
12%
Chemotherapy Agent
12%
Oropharynx Squamous Cell Carcinoma
12%
Erlotinib
12%
Pemetrexed
12%
Docetaxel
12%
Pleura Mesothelioma
12%
Clinical Trial
12%
Maximum Tolerated Dose
11%
Angiogenesis Inhibitor
8%
Epidermal Growth Factor Receptor
8%
Adverse Event
7%
Toxicity
6%
Neoplasm
5%
Malignant Neoplasm
5%
Metastasis
5%